Skip to Content
Merck
  • Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites.

Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites.

Nature communications (2020-04-05)
Nikolaus A Watson, Tyrell N Cartwright, Conor Lawless, Marcos Cámara-Donoso, Onur Sen, Kosuke Sako, Toru Hirota, Hiroshi Kimura, Jonathan M G Higgins
ABSTRACT

There are thousands of known cellular phosphorylation sites, but the paucity of ways to identify kinases for particular phosphorylation events remains a major roadblock for understanding kinase signaling. To address this, we here develop a generally applicable method that exploits the large number of kinase inhibitors that have been profiled on near-kinome-wide panels of protein kinases. The inhibition profile for each kinase provides a fingerprint that allows identification of unknown kinases acting on target phosphosites in cell extracts. We validate the method on diverse known kinase-phosphosite pairs, including histone kinases, EGFR autophosphorylation, and Integrin β1 phosphorylation by Src-family kinases. We also use our approach to identify the previously unknown kinases responsible for phosphorylation of INCENP at a site within a commonly phosphorylated motif in mitosis (a non-canonical target of Cyclin B-Cdk1), and of BCL9L at S915 (PKA). We show that the method has clear advantages over in silico and genetic screening.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
O-Phospho-L-tyrosine
Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
MISSION® esiRNA, targeting human HYAL2
Sigma-Aldrich
MISSION® esiRNA, targeting human AKT3
Sigma-Aldrich
MISSION® esiRNA, targeting human PRKACA
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Anti-γ-Tubulin (AK-15) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human AKT1, RP11-982M15.2
Sigma-Aldrich
MISSION® esiRNA, targeting human PRKACB